These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21561860)

  • 1. Bim protein degradation contributes to cisplatin resistance.
    Wang J; Zhou JY; Wu GS
    J Biol Chem; 2011 Jun; 286(25):22384-92. PubMed ID: 21561860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.
    Kawabata T; Tanimura S; Asai K; Kawasaki R; Matsumaru Y; Kohno M
    J Biol Chem; 2012 Mar; 287(13):10289-10300. PubMed ID: 22270368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
    Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
    Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.
    Yuan Z; Wang F; Zhao Z; Zhao X; Qiu J; Nie C; Wei Y
    PLoS One; 2011; 6(5):e20586. PubMed ID: 21655183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.
    Li Z; Zhang J; Liu Z; Woo CW; Thiele CJ
    Cell Death Differ; 2007 Feb; 14(2):318-26. PubMed ID: 16778834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
    Hazlehurst LA; Argilagos RF; Dalton WS
    Br J Haematol; 2007 Jan; 136(2):269-75. PubMed ID: 17233818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
    Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
    J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
    Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
    Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
    Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
    Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
    Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
    Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons.
    Meller R; Cameron JA; Torrey DJ; Clayton CE; Ordonez AN; Henshall DC; Minami M; Schindler CK; Saugstad JA; Simon RP
    J Biol Chem; 2006 Mar; 281(11):7429-36. PubMed ID: 16431916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
    Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
    Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.
    Wang J; Zhou JY; Zhang L; Wu GS
    Cell Cycle; 2009 Oct; 8(19):3191-8. PubMed ID: 19755862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells.
    Chen K; Tu Y; Zhang Y; Blair HC; Zhang L; Wu C
    J Biol Chem; 2008 Feb; 283(5):2508-17. PubMed ID: 18063582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
    Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
    Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.